M&T Bank Corp raised its position in Masimo Corporation (NASDAQ:MASI - Free Report) by 218.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,585 shares of the medical equipment provider's stock after buying an additional 6,578 shares during the quarter. M&T Bank Corp's holdings in Masimo were worth $1,247,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Masimo by 5.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,698 shares of the medical equipment provider's stock valued at $1,261,000 after buying an additional 508 shares during the period. Krilogy Financial LLC bought a new position in Masimo in the 4th quarter valued at about $471,000. Lecap Asset Management Ltd. bought a new position in Masimo in the 4th quarter valued at about $1,716,000. Merit Financial Group LLC bought a new position in Masimo in the 4th quarter valued at about $388,000. Finally, CWM LLC increased its holdings in Masimo by 2,045.3% in the 4th quarter. CWM LLC now owns 18,535 shares of the medical equipment provider's stock valued at $2,411,000 after buying an additional 17,671 shares during the period. 85.96% of the stock is owned by institutional investors.
Masimo Stock Down 0.0%
NASDAQ:MASI opened at $178.46 on Thursday. The firm's 50 day simple moving average is $177.15 and its 200 day simple moving average is $153.72. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.47. Masimo Corporation has a one year low of $125.94 and a one year high of $179.00. The company has a market cap of $9.59 billion, a PE ratio of -16.93, a P/E/G ratio of 1.81 and a beta of 1.20.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. BTIG Research lowered shares of Masimo from a "buy" rating to a "neutral" rating in a report on Wednesday, February 18th. Wolfe Research lowered shares of Masimo from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 19th. Wells Fargo & Company raised shares of Masimo to a "hold" rating in a report on Wednesday, March 18th. Piper Sandler lowered shares of Masimo from an "overweight" rating to a "hold" rating and set a $180.00 price target on the stock. in a report on Tuesday, February 17th. Finally, Raymond James Financial lowered shares of Masimo from an "outperform" rating to a "market perform" rating in a report on Friday, March 27th. Eight research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus target price of $181.17.
View Our Latest Stock Analysis on Masimo
Masimo Profile
(
Free Report)
Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.
In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.